Conatus Pharmaceuticals Inc (CNAT) Expected to Announce Quarterly Sales of $8.87 Million

Equities research analysts expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will report sales of $8.87 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The highest sales estimate is $12.50 million and the lowest is $7.00 million. Conatus Pharmaceuticals posted sales of $8.77 million in the same quarter last year, which would indicate a positive year over year growth rate of 1.1%. The firm is expected to announce its next earnings report on Wednesday, August 7th.

According to Zacks, analysts expect that Conatus Pharmaceuticals will report full-year sales of $30.36 million for the current year, with estimates ranging from $24.56 million to $40.00 million. For the next fiscal year, analysts expect that the business will report sales of $18.25 million, with estimates ranging from $1.50 million to $35.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Conatus Pharmaceuticals had a negative return on equity of 81.02% and a negative net margin of 57.46%. The business had revenue of $7.02 million during the quarter, compared to analyst estimates of $8.26 million.

A number of brokerages have issued reports on CNAT. HC Wainwright reissued a “hold” rating and issued a $1.50 price target on shares of Conatus Pharmaceuticals in a research note on Friday, May 3rd. Roth Capital reaffirmed a “neutral” rating and issued a $1.70 price objective on shares of Conatus Pharmaceuticals in a research note on Tuesday, March 26th. SunTrust Banks lowered Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Zacks Investment Research lowered Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $5.12.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of Conatus Pharmaceuticals by 13.4% in the 3rd quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock valued at $9,419,000 after purchasing an additional 191,287 shares in the last quarter. Sofinnova Investments Inc. boosted its position in shares of Conatus Pharmaceuticals by 18.4% in the 4th quarter. Sofinnova Investments Inc. now owns 638,197 shares of the biotechnology company’s stock worth $1,104,000 after purchasing an additional 99,282 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of Conatus Pharmaceuticals by 761.1% in the 4th quarter. Two Sigma Investments LP now owns 250,085 shares of the biotechnology company’s stock worth $433,000 after purchasing an additional 221,044 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Conatus Pharmaceuticals by 60.1% in the 1st quarter. Acadian Asset Management LLC now owns 245,078 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 91,956 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Conatus Pharmaceuticals by 19.4% in the 4th quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 33,827 shares during the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:CNAT traded down $0.01 during mid-day trading on Wednesday, reaching $0.91. The company’s stock had a trading volume of 286,000 shares, compared to its average volume of 919,259. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.01. Conatus Pharmaceuticals has a twelve month low of $0.69 and a twelve month high of $6.74. The firm has a market cap of $31.50 million, a price-to-earnings ratio of -1.54 and a beta of 3.11.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Further Reading: Institutional Investors

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.